FMTX - FMTX STOCK NEWS

Forma Therapeutics reported significant progress in its clinical programs targeting rare hematologic diseases and cancers, particularly in sickle cell disease (SCD) and prostate cancer. The etavopivat Phase 1 extension enrollment is complete, with updated results to be presented at the ASH Annual Meeting on December 11-14. Initial results for FT-7051 in metastatic prostate cancer demonstrated tolerability and clinical activity. Financially, Forma's cash position stands at $531.8 million, with projected runway lasting until Q3 2024.

Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) will release its third quarter 2021 financial results on November 12, 2021. The management will host a conference call at 8 a.m. ET to discuss the results and provide a business update. Investors can participate by calling (833) 301-1146 in the U.S. or (914) 987-7386 internationally, using Conference ID 6662686. A live webcast will be available on the company’s website.

Forma focuses on developing therapeutics for rare hematologic diseases and cancers, emphasizing innovation to meet high unmet medical needs.

Forma Therapeutics announced that four abstracts have been accepted for the 63rd American Society of Hematology Annual Meeting, taking place from Dec. 11-14, 2021. Notably, two oral presentations will share promising data on etavopivat, highlighting its positive tolerability profile and improvements in anemia for sickle cell disease patients. Additionally, data on olutasidenib will discuss its efficacy when used alone and in combination therapy for patients with mIDH1 acute myeloid leukemia. Both drugs are under investigation for their potential therapeutic benefits.

Mission BioCapital has announced the successful raising of $275 million for its latest fund, more than double the previous fund size. This new capital will focus on transformative early-stage investments in life sciences, including therapeutics, diagnostics, and drug delivery. The firm emphasizes partnerships with incubators like MBC BioLabs and Lab Central, fostering company creation in biotechnology. Mission BioCapital has already invested in seven companies from this fund, enhancing its commitment to support biotech entrepreneurs.

Forma Therapeutics (Nasdaq: FMTX) reported initial results from its Phase 1 trial of FT-7051, a novel CBP/p300 inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). The trial, titled Courage Study, demonstrates a favorable safety profile with no treatment discontinuations due to adverse events. One patient experienced a significant PSA decline of over 80% after 16 weeks. The adaptive design of the trial allows efficient exploration of dosing, with ongoing patient enrollment.

Forma Therapeutics Holdings (NASDAQ: FMTX), a clinical-stage biopharmaceutical firm, announced its participation in two investor conferences. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place from Sept. 20-23, 2021, with Forma presenting on Sept. 22, 2021 at 12:25 p.m. Eastern Time. The Cantor Global Healthcare Conference is scheduled for Sept. 27-30, 2021, where Forma will present on Sept. 27, 2021 at 10:40 a.m. Eastern Time. Recordings will be available on their website.

Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) reported its Q2 2021 financial results, revealing a net loss of $43.6 million, up from $25.4 million in Q2 2020. The company's cash position decreased to $570.8 million, projected to last through Q3 2024. Notably, clinical trials for etavopivat in sickle cell disease showed promising results, with 73% and 88% of patients achieving significant hemoglobin increases. The upcoming milestones include further trials in thalassemia and pediatric sickle cell patients. However, ongoing COVID-19 impacts could delay these initiatives.

Forma Therapeutics Holdings (Nasdaq: FMTX) will release its second quarter 2021 financial results on August 13, 2021. An investment community conference call is scheduled for 8 a.m. ET on the same day to discuss these results and provide a business update. Interested investors can join the call via telephone or a live webcast on Forma's website.

Forma Therapeutics is dedicated to developing innovative therapies for rare hematologic diseases and cancers, utilizing their deep biological insights and clinical development capabilities.

Forma Therapeutics Holdings (Nasdaq: FMTX) appointed John E. Bishop, Ph.D., as senior vice president and chief technology officer. Dr. Bishop will oversee chemistry, manufacturing, and control (CMC) functions, boosting drug development and commercialization efforts. He brings extensive experience in oncology and hematology from his previous roles at Epizyme and Momenta Pharmaceuticals. The leadership change aims to enhance technical capabilities and innovate solutions for rare hematologic diseases and cancers, reinforcing Forma's commitment to patient care.